Table 5.

Major results of the meta-analysis.

Outcome	Cumulative	CTP A vs. B	vs. TKIs	1st line vs. 2nd line
PFS	6.86 m (6.31–7.41)	MD: 3.83 m (1.81–5.84)∗∗	MD: 2.27 m (0.94–3.5)∗∗	MD: 0.58 m (−0.18 to 1.35)
OS	13.8 months (11.81–15.8)	MD: 7.19 (4.85–9.53)∗∗	OR, 0.67 (0.58–0.78)∗∗	MD:3.52 m (−1.42 to 8.46)
ORR
RECIST	26.7% (24.6–29.1)	OR, 1.42 (0.77–2.6)	OR, 1.44 (1.01–2.04)∗	OR, 1.82 (1.3–2.53)∗∗
mRECIST	34% (30.3–37.8)	OR, 1.33 (0.52–3.39)	OR, 1.33 (1.01–1.75)∗	OR, 2.02 (1.34–3.05)∗∗
DCR
RECIST	75.3% (73.1–77.4)	OR, 1.61 (0.92–2.82)	OR, 1.18 [0.83–1.66]	OR,1.38 (1.008–1.89)∗
mRECIST	73.6% (68.8–78)	OR, 2.23 (1.06–4.67)∗	OR, 12 (7.54–19.11)∗∗	OR, 1.5 (0.89–2.5)
Grade 3 adverse events	31.8% (25.6–38.7)	OR,0.89 (0.45–1.74)	OR, 0.86 (0.61–1.2)	–

PFS, progression-free survival; OS, overall survival; m, months; MD, mean difference; OR, odds ratio; RECIST, Response Evaluation Criteria in Solid Tumours; mRECIST, modified RECIS; TKIs, Tyrosine Kinase inhibitors.

∗P < 0.05; ∗∗P < 0.001.